Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/3/2025 | Buy → Hold | Berenberg | |
4/15/2025 | $35.25 | Neutral | Exane BNP Paribas |
2/12/2025 | Equal-Weight | Morgan Stanley | |
11/15/2024 | Buy → Hold | Deutsche Bank | |
11/12/2024 | $53.00 → $39.50 | Buy → Hold | Jefferies |
10/31/2024 | Buy → Neutral | Guggenheim | |
7/8/2024 | Buy → Neutral | UBS | |
5/30/2024 | $47.00 | Neutral | Goldman |
SC 13G/A - GSK plc (0001131399) (Subject)
SC 13G/A - GSK plc (0001131399) (Subject)
SC 13G/A - GSK PLC (0001131399) (Subject)
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved$225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billionFirst outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning exces
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigation
Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype characterized by blood eosinophil count (BEC) starting at 150 cells/μL Approval based on the positive MATINEE and METREX phase III trials MATINEE data included reduction of exacerbations leading to hospitalization and/or emergency department visits Nearly 70% of patients in the US who are inadequately controlled on inhaled triple therapy have a BEC ≥150 cells/μL GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinoph
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
Berenberg downgraded GlaxoSmithKline from Buy to Hold
Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25
Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight
Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab
4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of approximately 33% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes.Announced a non-exclusive data license with GSK plc (NYSE:GSK) for novel drug target discovery and other research. U